Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Patrick P. Ng, PhD, Mehrdad Mobasher, MD MPH, Kitman S. Yeung, MS, Andrew N. Hotson, PhD, Craig M. Hill, PhD, Antonett Madriaga, MS, Trang P. Dao-Pick, MA, Erik Verner, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Richard A. Miller, MD, Joseph J. Buggy, PhD, James W. Janc, PhD

Blood (2019) 134 (Supplement_1): 1571.

https://doi.org/10.1182/blood-2019-127338

Published: 2019

Journal Articles

Toll-Like Receptor and Autoimmunity.

Mark Shlomchik, MD, PhD, Kevin Nickerson, Rebecca Sweet, Sean Christensen, Robin Herlands

Blood (2009) 114 (22): SCI-24.

https://doi.org/10.1182/blood.V114.22.SCI-24.SCI-24

Published: 2009

Journal Articles

Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/ lpr mice

Pierre Bobé, Danielle Bonardelle, Karim Benihoud, Paule Opolon, Mounira K. Chelbi-Alix

Blood (2006) 108 (13): 3967–3975.

https://doi.org/10.1182/blood-2006-04-020610

Published: 2006

Journal Articles

Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses

Xiaosong Wang, Atsushi Kumanogoh, Chie Watanabe, Wei Shi, Kanji Yoshida, Hitoshi Kikutani

Blood (2001) 97 (11): 3498–3504.

https://doi.org/10.1182/blood.V97.11.3498

Published: 2001

Journal Articles

Intra–bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice

Taketoshi Kushida, Muneo Inaba, Hiroko Hisha, Naoya Ichioka, Takashi Esumi, Ryokei Ogawa, Hirokazu Iida, Susumu Ikehara

Blood (2001) 97 (10): 3292–3299.

https://doi.org/10.1182/blood.V97.10.3292

Published: 2001

Journal Articles

Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation

Taketoshi Kushida, Muneo Inaba, Kenji Takeuchi, Kikuya Sugiura, Ryokei Ogawa, Susumu Ikehara

Blood (2000) 95 (5): 1862–1868.

https://doi.org/10.1182/blood.V95.5.1862.005k27_1862_1868

Published: 2000

NARROW

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Toll-Like Receptor and Autoimmunity.

Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/ lpr mice

Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses

Intra–bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice

Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation

Email alerts

ASH Publications

American Society of Hematology

Preliminary Clinical Data from a Phase 1 Trial with CPI-818, a Selective ITK Inhibitor That Preferentially Blocks the Growth of T Lymphoma Cells

Toll-Like Receptor and Autoimmunity.

Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/ lpr mice

Functional soluble CD100/Sema4D released from activated lymphocytes: possible role in normal and pathologic immune responses

Intra–bone marrow injection of allogeneic bone marrow cells: a powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice

Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only